Currently, the company is focused on developing new treatments for pancreatic and brain cancers, as well as autoimmune conditions like cutaneous lupus erythematosus (CLE), it is leveraging in-house expertise and strategic partnerships to build a robust drug pipeline. In an interview, CEO & Managing Director Dr Gisela Mautner sheds light on Noxopharm’s platform, RNA research landscape, and how Australian biotech is drawing international interest. Edited excerpts:
Tell us about Noxopharm and its portfolio of innovative treatments.
We are an Australian biotech with two highly innovative and proprietary technology platforms – Sofra for inflammation, autoimmunity, and mRNA vaccine enhancement, plus Chroma for oncology. We have a strong team of experienced leaders with over 100 years of combined pharma experience, as well as very talented scientists who are progressing our research on both fronts. We also work closely with research institutions and academia and take a very collaborative approach to our business.
How have the Chroma and Sofra platforms shaped the company’s approach to cancer and inflammation therapies?
Our Sofra platform has been developed from our close relationship with the Hudson Institute of Medical Research, based on over 20 years of research there into inflammation and related diseases. We are now seeing some very promising assets emerge from the platform, which is based on short nucleic acid sequences known as oligonucleotides. These provide a novel treatment approach, acting on specific cells to modulate inflammation at its source, and can therefore be applied in many different areas such as vaccines and autoimmune diseases where inflammation plays a central role.
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Nov 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Nov 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
"We are dedicated to helping people of all ages see brilliantly"
The global leader in eye care for over 75 years, Alcon Inc. strives to help eye care professionals strengthen their practices and serve patients better, improving visual health worldwide. Through its innovative eye care portfolios, Alcon has established operations in 56 countries and serves patients in 140 countries. Jason Hoffe, Vice President, APAC Vision Care, Alcon, responsible for driving the vision care business in the region shares opportunities exist for the company and new developments in eye healthcare that are cause for optimism for patients in the region.
Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation
In the current pharmaceutical manufacturing environment, linking information technology (IT) with operational technology (OT) systems is increasingly vital. This integration enables a seamless exchange of information between these two historically separate domains - one focused on data management and the other on overseeing physical operations. This enables various aspects of the manufacturing process to gain insights from one another to boost efficiency and refine strategic decision-making. Digital transformation is essential for directing companies through the complexities of implementation and ensuring a seamless shift to a data-driven, digitally optimized manufacturing landscape.
Building the Future of Medicine
PRODUCT OF THE YEAR 2024 - Needle Free Injection System technology by IntegriMedical
Emerging Leader in Cell & Gene Therapy
STARTUP OF THE YEAR 2024 - ImmunoACT
Improving Access for Respiratory Healthcare
STARTUP OF THE YEAR 2024 - Aevice Health
Making an Impact with a 'CliKX'
Dr Lynne Lim, Co-Founder & Chief Executive Officer, NousQ
Eyeing 20-20 Vision of Excellence
Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research
Refining the Use of Radiation
Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals
Honouring Innovators in Asia's Thriving Life Sciences Sector
Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.
How To Control Indian Diabetes Growth
World Diabetes Day, observed on November 14, reminds us of the growing impact of diabetes on global health and the urgent need for collective action to prevent, diagnose, and manage this chronic condition. In 2024, the theme 'Breaking Barriers, Bridging Gaps' underscores the critical importance of accessible, high-quality diabetes care, especially for underrepresented communities. The Government of India has taken many measures intending to reduce the prevalence of diabetes and alleviate its long-term complications, contributing to a healthier future for all citizens.
